XRP takes center stage as Wellgistics Health files with the SEC to adopt it as both a treasury reserve and payments engine across its healthcare and tech operations.
Listen to article WRITTEN BY 
Kevin Helms 
Wellgistics Health Unveils XRP Strategy in SEC Filing With Dual Focus on Reserve and Payments
Wellgistics Health Inc. (Nasdaq: WGRX) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 24 to pursue a public offering of its common stock and related warrants. The offering will be conducted on a reasonable best efforts basis through a placement agent and has no minimum threshold for closing. The securities include shares of common stock, prefunded warrants, and placement agent warrants.
In its preliminary prospectus, Wellgistics outlined a strategic shift toward digital asset integration, centered on XRP. The company declared:
We intend to adopt XRP as a treasury reserve asset on an ongoing basis, subject to market conditions and our anticipated cash needs.
It views XRP as a means to enhance financial flexibility and improve transaction efficiency across its healthcare distribution and technology network.
The company further detailed how it plans to accumulate XRP: Our strategy includes acquiring and holding XRP using cash flows that exceed working capital requirements, and from time to time, subject to market conditions, issuing equity or debt securities or engaging in other capital raising transactions with the objective of using the proceeds to purchase XRP. We expect that we will continue to accumulate XRP after adopting it as our primary treasury reserve asset.
Beyond reserve holdings, Wellgistics intends to operationalize XRP in its payments infrastructure, stating:
We intend to integrate blockchain payment solutions into our platform to accept payments in XRP. Our management expects that this capability will expand customer payment options while enabling us to hold and transact in these assets directly.
While the filing emphasized XRPs utility as a real-time settlement tool and inflation hedge, the company acknowledged significant regulatory uncertainties. Although a May 2025 settlement resolved the SECs litigation against Ripple Labs concerning certain XRP sales, Wellgistics noted that a definitive regulatory classification remains unresolved.
